Our Women's Health Network
The Women’s Health Innovation Series is the leading network connecting pharma, biotech, medical device companies, start-ups, investors, payers, researchers, and HCPs to drive innovation at the convergence of healthcare and technology.
Our community spans over 30,000 senior global decision makers in the space. Discover our audience breakdown below...
WHI SERIES ADVISORY BOARD 2022
The Global Advisory Board is a prestigious group of individuals with extensive experience in the women's health industry. This group is responsible for guiding the production and development of the global Women's Health Innovation Series.
For enquiries please email [email protected]
Alice Zheng, MD, MBA, MPH
Susan Nicholson
Jamie White
Dr. Stephen Gerrard Ph.D.
Kalahn Taylor-Clark, PhD MPH
Valerie Palmieri
Kelle Moley, MD
Dr. Kelle Moley is a career physician-scientist obstetrician/gynecologist who currently leads the Reproductive Health Technologies Domain within the Discovery & Translational Sciences, Global Health Division at the Bill and Melinda Gates Foundation. Kelle joined BMGF in July 2020, with a 30-year history of basic and translational research on reproductive health issues in females throughout the life course-- from organismal to cellular and molecular levels of metabolic, developmental biology, embryo implantation and decidualization, and infectious diseases of the female reproductive tract.
Kelle earned her BA from Wellesley College, and her MD from Yale Medical School. Thereafter, she pursued an Obstetrics & Gynecology Residency and a Fellowship in Reproductive Endocrinology & Fertility at Washington University in St. Louis School of Medicine. Kelle then spent the next 3 decades of a thriving research career at Washington University—rising to become the James P. Crane Professor of Obstetrics & Gynecology, Vice Chair of Obstetrics & Gynecology, Chief of the Division of Basic & Translational Research for the Department of Obstetrics & Gynecology, Co-Director of the Institute of Clinical & Translational Science for the School of Medicine, and Director of the Center for Reproductive Health Sciences at the School of Medicine. Her research (published in some 150 peer-reviewed primary articles) led to an international reputation along with numerous honors, including election to the National Academy of Medicine in 2014. She also earned a reputation as a superb mentor to trainees, leading the reproductive endocrinology fellowship program at Washington University until she left academia in 2018. After a 2-year stint as Chief Scientific Officer and Senior Vice President of the March of Dimes she left to pursue her new position at BMGF.
TESTIMONIALS & SUCCESS STORIES
2023 Audience Breakdown
Want to discover our leading network of women's health leaders? Take a look at our unmatched audience statistics...
For a full audience breakdown, please view our Media Pack.
-
Senior Leaders
Looking to attract senior leaders? Our Summits bring together a 40% C-Level attendance. We can help you make the right connections....
Want to discover our bespoke marketing offerings? View our Marketing Solutions Pack and learn more about our range of Lead Generation, Thought Leadership, Brand Awareness and Market Insight products.
Featured Speakers
Insight into the market dynamics that are having the greatest impact on an industry is what drives our business and its this understanding that allows us to identify and secure the thought leaders who have a true 'vision' to offer. This is a small sample of some of those visionaries that are helping shape the future of women's health.
David Sable
Elizabeth Garner
Elizabeth Garner, MD, MPH is the US Chief Scientific Officer of Ferring Pharmaceuticals, a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within orthopedics and gastroenterology including microbiome therapeutics.
Dr. Garner has nearly 30 years of experience in medicine and industry. Prior to joining Ferring in 2022, she held Chief Medical Officer roles for ObsEva, a women’s health biotechnology company, and Agile Therapeutics, a women’s healthcare company focused on contraception. Earlier, she held leadership roles in medical affairs at Myriad Genetics Laboratories and clinical development at Abbott Laboratories and Merck Research Laboratories. Across her 16-year career in the pharmaceutical industry, she has led or contributed to several US product approvals, including the HPV vaccine-Gardasil®9, Orilissa®-an oral treatment for endometriosis, the novel Twirla® low-dose contraceptive patch, and Rebyota-the first FDA-approved live microbiota product for the prevention of recurrent Clostridium Difficile.
Dr. Garner is on the Board of Directors of Kezar Life Sciences (KZR), which develops novel therapies for autoimmune diseases and cancer. She is also on the Board of Directors of Sermonix Pharmaceuticals, which focuses on targeted therapies for breast cancer. Dr. Garner is also the current President of the American Medical Women’s Association, the oldest multispecialty organization dedicated to advancing women in medicine and improving women’s health.
Dr. Garner received joint M.D. and M.P.H. degrees from Harvard Medical (HMS) and Public Health Schools. She trained in obstetrics and gynecology at Brigham and Women’s (BWH)/Massachusetts General Hospitals and completed a fellowship in gynecologic oncology at BWH/Dana Farber Cancer Institute. Prior to transitioning into industry, she was an Assistant Professor at HMS, where she focused on academic clinical practice in gynecologic oncology, basic science ovarian cancer research and teaching and mentorship of residency and fellowship trainees and medical students. Dr. Garner is a frequent panelist and speaker on a range of topics including innovation and investment in women’s health, women’s leadership and diversity, equity, and inclusion (DEI). She is an author of close to 40 peer-reviewed scientific papers. Dr. Garner was also a 2019 awardee of the PharmaVoice 100 Most Inspiring Individuals in the life sciences industry and is the 2022 recipient of the Woman in Science Award from the American Medical Women’s Association.
Ru-fong Cheng
Temitayo Erogbogbo
Dr. Neel Shah
Erica Kantor
Keren Leshem, MBA
Seasoned executive with over 20 years' experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD and financing.
Sarah Chamberlain
Elizabeth Bailey
Evan Sussman
Evan is the Chief Executive Officer and a Co-Founder of Granata Bio, a US based biopharma company focused on women’s health and fertility. In his role, Evan is responsible for Granata Bio’s corporate, customer, and commercial strategies.
Before founding Granata Bio, Evan spent nine years at EMD Serono/Merck KgAA. Most recently, he served as the Marketing and Business Unit Head for the US Fertility/Fertility Technologies businesses. During this time, Evan spearheaded the creation of innovative programs aimed at expanding access to care for under-recognized patient groups. He has previously served on the corporate council of RESOLVE: The National Infertility Association and the American Society of Reproductive Medicine.
Evan is a graduate of Brown University and received an MBA in Healthcare Leadership from Yale University. He lives in the Boston area with his wife and daughter.
Rachel Blank
Brian T. Nguyen
Strategic Partners
From the market leading Women's Health and Femtech Companies to the most well respected CEOs, Founders, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors, our Strategic Partners continue to play a pivotal role in how we help shape the future of Women's Health. For more information on how to become a strategic partner, please visit our Marketing Solutions page
